araag2/HINT huggingface dataset:
Clinical trial NCT00523939 (phase 2, status: terminated)
Conditions: neoplastic meningitis, lymphoma, b cell
ICD codes: I78.1, D63.0, M36.1, Q82.5, R53.0, G73.1, M36.0, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cytarabine liposome injection
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Reason stopped: 
    low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Cytologically confirmed, or radiographic evidence for lymphomatous or leukemic
             meningitis. If the CSF cytology is negative, patients must have MRI/CT brain and
             clinical findings consistent with neoplastic meningitis.

          -  Karnofsky Performance Score of 60 or above.

          -  Age ≥ 18 years.

          -  Patients must have adequate hematologic, renal and liver function. Laboratory

          -  Absolute neutrophil count (ANC) ≥ 1,500/mm3 or white blood cell count > 3,000/mm3

          -  Platelet count ≥ 100, 000/mm3

          -  BUN and serum creatinine must be ≤ 1.5 times upper limit of laboratory normal

          -  Total and direct serum bilirubin must be ≤ 1.5 times upper limit of laboratory normal

          -  SGOT and SGPT ≤ 3.0 times upper limit of laboratory normal

          -  Alkaline phosphatase derived from liver ≤ 2.0 times upper limit of laboratory normal

          -  No uncontrolled infection other than human immunodeficiency virus that is being
             treated with anti-retroviral therapy

          -  Patients who have had prior CNS radiation, prior intrathecal methotrexate, and prior
             CNS prophylaxis with intrathecal or intravenous cytarabine or methotrexate are
             eligible

          -  Written informed consent

        Exclusion Criteria:

          -  Experimental/Investigational chemotherapy, immunotherapy, or biologic therapy within
             four weeks prior to study

          -  Concurrent systemic chemotherapy with high dose methotrexate, high dose cytarabine, or
             high dose thiotepa (they cross the blood brain barrier at high levels)

          -  Patients receiving whole brain radiotherapy or craniospinal irradiation

          -  Previous (less than 2 years from diagnosis) or concurrent malignancies at other sites
             with the exception of fully treated carcinoma in situ of the cervix, basal cell
             carcinoma of the skin, and squamous cell carcinoma of the skin, or prostate cancer not
             requiring ongoing chemotherapy

          -  Pregnant or lactating women

          -  Known active meningeal infection

          -  Evidence of obstructive hydrocephalus requiring neurosurgical intervention
Clinical trial NCT01092065 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: afq056 with l-dopa, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with Parkinson's Disease (PD), treated with L-dopa, experiencing OFF time
             and dyskinesias for at least three months

        Exclusion Criteria:

          -  Surgical treatment for PD

          -  Cancer within the past 5 years (other than localized skin cancer and prostate cancer
             that has been effectively treated)

          -  Advanced, severe or unstable disease (other than PD) that may interfere with the study
             outcome evaluations

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00737932 (phase 2, status: completed)
Conditions: crohn's disease
ICD codes: K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: laquinimod
SMILES: CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects diagnosed with Crohn's disease for at least 3 months prior to screening.

          2. Moderate to severe Crohn's disease patients as determined by the CDAI score

        Exclusion Criteria:

          1. Subjects who have had recent bowel surgery

          2. Subjects with clinically significant GI obstructive symptoms

          3. Subjects with a clinically significant or unstable medical or surgical condition

          4. Subjects with unstable doses of standard of care medications (5-ASA, antibiotics, oral
             corticosteroids, immunosuppressants )

          5. Women who are pregnant or nursing or who intend to be during the study period.

          6. Women of child-bearing potential who do not practice an acceptable method of birth
             control
Clinical trial NCT01414075 (phase 2, status: completed)
Conditions: dialysis, anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: fg-4592
SMILES: CC1=NC(C(=O)NCC(O)=O)=C(O)C2=CC=C(OC3=CC=CC=C3)C=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18 to 80 years

          2. Receiving hemodialysis or peritoneal dialysis for end- stage renal disease (ESRD) for
             2 weeks to 4 months.

          3. Hemoglobin < 10 g/dL

          4. Body weight 40 to 140 kg

        Exclusion Criteria:

          1. Previously received erythropoiesis-stimulating agents

          2. Received IV iron within 4 weeks prior to randomization

          3. Received red blood cell transfusion within 8 weeks prior to randomization

          4. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab)

          5. History of chronic liver disease

          6. Clinically significant infection

          7. New York Heart Association Class III or IV congestive heart failure

          8. History of cancer within the past 4 years

          9. Chronic inflammatory disease even if it is in remission

         10. History of other blood disorders

         11. Active hemolysis or diagnosis of hemolytic syndrome

         12. Known bone marrow fibrosis

         13. Uncontrolled or symptomatic secondary hyperparathyroidism

         14. History of alcohol or drug abuse

         15. History of allergy or sensitivity to oral or intravenous iron

         16. Heart attack, deep vein thrombosis, or pulmonary embolism in the past 3 months

         17. Seizure disorder or receiving anti-epilepsy medication

         18. Pregnant or breast-feeding females
Clinical trial NCT00225303 (phase 2, status: completed)
Conditions: hiv infection
ICD codes: Z21
Drugs: tmc125
SMILES: CC1=CC(=CC(C)=C1OC1=C(Br)C(N)=NC(NC2=CC=C(C=C2)C#N)=N1)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age 18 years or older

          -  Documented HIV-1 infection

          -  Stable NNRTI-containing ART (minimum 12 weeks) at screening OR treatment interruption
             (minimum 4 weeks) at screening OR having received an NNRTI alone or in combination
             with other ARVs for prevention of MTCT

          -  Plasma viral load at screening above 1000 HIV-1 RNA copies/ml

          -  Prior NNRTI-experience with documented genotypic evidence of resistance to currently
             available NNRTIs (defined as at least one NNRTI-associated mutation per IAS-USA Drug
             resistance Mutation guidelines)

          -  Sensitive to the 2 NRTIs to be used as underlaying ART

          -  Subject has given informed consent

        Exclusion Criteria:

          -  Previous treatment with Protease Inhibitors

          -  Presence of any currently active AIDS defining illness except stable cutaneous
             Kaposi's Sarcoma and Wasting syndrome due to HIV infection

          -  Current or past history of alcohol and/or drug use which, in the investigator's
             opinion, would compromise the subject's safety or compliance to the study protocol
             procedures

          -  Acute Hepatitis A, B or C or chronic hepatitis B or C with elevated LFTs of > 3 times
             ULN
Clinical trial NCT00368641 (phase 2, status: terminated)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: extraneal
SMILES: [Na+].[Cl-]
Reason stopped: 
    enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with congestive heart failure (CHF) who remain fluid overloaded despite
             standard treatment.

        Exclusion Criteria:

          -  Patients who have reversible CHF or have diseases or conditions that would
             contraindicate the use of peritoneal dialysis.
Clinical trial NCT00354224 (phase 2, status: terminated)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed gastric cancer

               -  Locally advanced, unresectable, or metastatic disease

          -  Measurable disease, defined as at least 1 lesion that can be accurately measured in ≥
             1 dimension as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%

          -  WBC ≥ 3,000/mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Bilirubin normal

          -  AST/ALT ≤ 2.5 times upper limit of normal

          -  Creatinine ≤ 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during study and for 6 months after
             completion of study treatment

          -  Able to swallow

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to fluoropyrimidines or platinum chemotherapy agents

          -  No uncontrolled intercurrent illness including, but not limited to the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness or social situations that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas
             or mitomycin C) and recovered

          -  At least 6 months since prior radiotherapy with capecitabine as a radioenhancer

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent chemotherapy

          -  No concurrent palliative radiotherapy

          -  No concurrent hormonal therapy except for the following:

               -  Steroids for adrenal failure

               -  Hormones for nondisease related conditions (e.g., insulin for diabetes)

               -  Intermittent use of dexamethasone as an antiemetic

          -  No other concurrent investigational agents

          -  No other concurrent anticancer agents or therapies
Clinical trial NCT00386009 (phase 2, status: completed)
Conditions: benign prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: tadalafil, placebo
SMILES: [H][C@]12CC3=C(NC4=CC=CC=C34)[C@H](N1C(=O)CN(C)C2=O)C1=CC2=C(OCO2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men 40 years of age or older with Lower Urinary Tract Symptoms (LUTS) with a total
             International Prostate Symptom Score (IPSS) greater than or equal to 13 at Visit 1.

          -  Agree not to use any other approved or experimental medications for Benign Prostate
             Hyperplasia (BPH)-Lower Urinary Tract Symptoms, including alpha blockers, 5-alpha
             reductase inhibitors, PDE5 inhibitors, or herbal preparations at any time during the
             study.

          -  Have not taken finasteride or dutasteride therapy for at least 4 months prior to Visit
             2; have not taken any other LUTS therapy (including herbal preparations) or PDE5
             inhibitors for at least 4 weeks prior to Visit 2.

          -  Have had BPH-LUTS for greater than 6 months prior to Visit 1.

        Exclusion Criteria:

          -  Any pelvic surgical procedure on the urinary tract, including minimally invasive
             BPH-LUTS therapies and penile implant surgery.

          -  History of urethral obstruction due to stricture, valves, sclerosis, or tumor.

          -  Current neurologic disease or condition associated with neurogenic bladder (for
             example, Parkinson's disease, multiple sclerosis).

          -  History of cardiac conditions including myocardial infarction, bypass surgery,
             angioplasty or stent placement for a specified time before starting the study.

          -  History of angina requiring treatment with nitrates.

          -  Prostate Specific Antigen (PSA) greater than 10 nanogram/milliliter (ng/ml) at Visit
             1.
Clinical trial NCT00104884 (phase 2, status: terminated)
Conditions: malignant melanoma, melanoma
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10, C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: depsipeptide
SMILES: C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C
Reason stopped: 
    the study was terminated on may 17, 2006 due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Stage III unresectable or American Joint Committee on Cancer (AJCC) stage IV
             cutaneous, mucosal, ocular, or unknown primary melanoma with measurable disease by
             physical examination or imaging studies.

          -  Palpable cutaneous or nodal metastases suitable for punch, trucut, or similar biopsy
             if the patient agrees.

          -  Normal electrocardiogram (EKG)

          -  Left ventricular ejection fraction (LVEF) > 40% by Multi Gated Acquisition Scan (MUGA)

          -  Corrected QT (QTc) < 500 msec

          -  Age greater than or equal to 18

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  Normal organ and marrow function

          -  Patients on hydrochorthiazide should be switched to a potassium-sparing diuretic or
             another antihypertensive

          -  At least 4 weeks since prior radiotherapy

          -  Patients with cardiac hypertrophy may be enrolled but should be carefully monitored.

        Exclusion Criteria:

          -  Prior FR901228 (depsipeptide)

          -  Prior chemotherapy

          -  Other concurrent chemotherapy

          -  Active central nervous system (CNS) metastases by brain computed tomography (CT) scan
             or magnetic resonance imaging (MRI)

          -  History of coronary atherosclerotic heart disease

          -  History of myocardial infarction

          -  History of congestive heart failure

          -  Non-melanoma malignancy within the past 5 years except carcinoma in situ or squamous
             cell or basal cell skin cancer

          -  Pregnant or nursing women

          -  Conditions that in the opinion of the investigator would interfere with the ability of
             the patient to complete this protocol

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Depsipeptide

          -  Co-medication with an agent that causes QTc prolongation

          -  Human immunodeficiency virus (HIV) positive patients receiving combination
             anti-retroviral therapy

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Concurrent radiotherapy

          -  Left ventricular hypertrophy (LVH) on their baseline EKG tracing
Clinical trial NCT00105040 (phase 2, status: completed)
Conditions: epilepsy, partial
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: levetiracetam
SMILES: CC(C)CC1=CC=C(C=C1)C(C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pediatric subjects (4 - 16 years old) diagnosed with refractory partial onset seizures
             for a minimum of six months prior to Visit 1 experiencing at least two partial onset
             seizures during the four weeks prior to Visit 1 will be enrolled

          -  Subjects should be on a stable regimen of one or a maximum of two other antiepileptic
             drugs (AEDs) for at least 2 weeks prior to Visit 1

          -  Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least
             70

          -  Subject and parent/guardian should be fluent in English

        Exclusion Criteria:

          -  Subject must not have had previous treatment with levetiracetam unless, in the opinion
             of the investigator, the subject's previous treatment was inadequate in dose or
             duration to provide an accurate assessment of the therapy, or the effect of
             levetiracetam was confounded by concomitant medication

          -  Subject is receiving benzodiazepines on a routine or chronic basic and is unable to
             discontinue use four weeks prior to Visit 1

          -  Subject has seizures too close together to accurately count

          -  Subject has a current psychiatric disorder other than mild to moderate attention
             deficit, behavior, or learning disorders
Clinical trial NCT00344552 (phase 2, status: completed)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have measurable disease

          -  Patients must have experienced on pervious chemotherapy regime

          -  Men and Women, with the age 20 years or older

          -  ECOG PS: 0-1

        Exclusion Criteria:

          -  Patients with previous therapy with Taxanes
Clinical trial NCT01381094 (phase 2, status: completed)
Conditions: anemia, kidney disease
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: akb-6548, placebo
SMILES: OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  18 to 79 years of age, inclusive

          -  Chronic Kidney Disease (eGFR <60 mL/min), not yet on dialysis

          -  Hemoglobin (Hgb) ≤ 10.5 g/dL

          -  TSAT ≥ 20%

          -  Ferritin ≥ 50 ng/mL

        Key Exclusion Criteria:

          -  BMI >42

          -  Red blood cell transfusion within 12 weeks

          -  Androgen therapy within the previous 21 days prior to study dosing

          -  Therapy with any approved or experimental erythropoiesis stimulating agent (ESA)
             within the 11 weeks prior to the Screening visit

          -  Subjects meeting the criteria of ESA resistance within the previous 4 months

          -  Individual doses of intravenous iron of greater than 250 mg within the past 21 days

          -  AST or ALT >1.8x ULN

          -  Alkaline phosphatase >2x ULN

          -  Total bilirubin >1.5x ULN

          -  Uncontrolled hypertension

          -  New York Heart Association Class III or IV congestive heart failure

          -  Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to
             dosing
Clinical trial NCT01056315 (phase 2, status: terminated)
Conditions: painful diabetic neuropathy
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: grt3938y, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    trial was stopped due to difficult enrolment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Symmetrical painful diabetic peripheral neuropathy

        Exclusion Criteria:

          -  History of hypersensitivity, allergy or contraindication to opioids and acetaminophen

          -  Confounding painful conditions

          -  Significant vascular disease

          -  History or risk of seizure

          -  Chronic disease that might effect drug absorption, distribution, metabolism, or
             excretion

          -  Female subjects who are being pregnant or breastfeeding

          -  Evidence or history of alcohol, medication, or drug abuse
Clinical trial NCT00025493 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed breast cancer

               -  Distant metastatic disease confirmed by histology, cytology, or strong clinical
                  evidence

          -  Measurable disease

          -  No known brain or CNS metastases

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  70 and over OR

          -  Under 60

        Sex:

          -  Female

        Menopausal status:

          -  Not specified

        Performance status:

          -  Zubrod 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Hemoglobin at least 9 g/dL

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than upper limit of normal (ULN)

          -  SGOT or SGPT no greater than 1.5 times ULN (2.0 times ULN if liver metastases are
             present)

          -  Alkaline phosphatase no greater than 1.5 times ULN (2.0 times ULN if liver metastases
             are present)

        Renal:

          -  Creatinine no greater than ULN

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No other prior malignancy within the past 5 years except adequately treated basal cell
             or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer in complete remission

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent immunotherapy for breast cancer

        Chemotherapy:

          -  Prior adjuvant or neoadjuvant chemotherapy allowed

          -  Prior adjuvant taxanes allowed

          -  No other concurrent chemotherapy for breast cancer

        Endocrine therapy:

          -  Prior hormonal therapy in the adjuvant setting or for metastatic disease allowed

          -  No concurrent hormonal therapy for breast cancer

        Radiotherapy:

          -  No concurrent radiotherapy for breast cancer

        Surgery:

          -  Not specified

        Other

          -  No more than 1 prior regimen for advanced, recurrent, or metastatic disease